A Case of Chronic Thrombocytopenia in a 17-Year-Old Female A Case of Chronic Thrombocytopenia in a 17-Year-Old Female
A case of gray platelet syndrome, a rare type of thrombocytopenia, is discussed. How is this disorder diagnosed and treated?Laboratory Medicine (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 12, 2020 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Amanita fuliginea poisoning with thrombocytopenia: a case series - Wang Q, Sun M, Lv H, Lu P, Ma C, Liu Y, Liu S, Tong H, Hu Z, Gao Y.
We present 3 cases of severe A. fuliginea poisoning associated with thrombocytopenia in China. Three patients consumed foraged A. fuliginea and developed nau... (Source: SafetyLit)
Source: SafetyLit - February 3, 2020 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma
This case of severe grade V thrombocytopenia caused by nivolumab highlights the need for clinicians to be aware of this potential adverse effect of immune-checkpoint inhibitors.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia
DURHAM, N.C., Jan. 13, 2020 -- (Healthcare Sales & Marketing Network) -- Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), has been granted Orphan Drug Designation1 (ODD) by the US Food and Drug Administr... Biopharmaceuticals, Oncology, FDA Dova Pharmaceuticals, avatrombopag, Chemotherapy-Induced, Thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 13, 2020 Category: Pharmaceuticals Source Type: news

Avatrombopag cost  effective for thrombocytopenia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2020 Category: Drugs & Pharmacology Source Type: news

Romiplostim for Chemotherapy-Induced Thrombocytopenia Romiplostim for Chemotherapy-Induced Thrombocytopenia
Does the thrombopoietin receptor agonist romiplostim expedite correction of thrombocytopenia caused by chemotherapy?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

How Does Gaucher Disease Present?
Discussion Gaucher disease (GD) was first described by Philippe Gaucher in 1882. It was the first lysosomal storage disease (LSD) described and is the comparison prototype for many variations and their treatment. There are about 50 LSD and more well-known ones include Fabry, Niemann-Pick and Pompe diseases. LSDs currently have more than 300 different enzymes or membrane proteins affected which cause central nervous system and visceral disease. Overall the frequency of LSDs in aggregate is 1:3000 – 7000 live births. GD has an estimated prevalence of 1:57,000 – 111,000. It is higher within the Ashkenazi Jewish po...
Source: PediatricEducation.org - December 9, 2019 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

EMA Panel Backs Fostamatinib (Tavalisse) for Chronic ITP EMA Panel Backs Fostamatinib (Tavalisse) for Chronic ITP
Fostamatinib, a spleen tyrosine kinase inhibitor, helps increase and maintain the platelet count and reduce bleeding risk in adults with chronic immune thrombocytopenia refractory to other treatments.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Med... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, fostamatinib, immune thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2019 Category: Pharmaceuticals Source Type: news

Nplate ® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia (ITP), a rare, serious autoimmune disease characterized by low platelet counts. (Source: World Pharma News)
Source: World Pharma News - October 21, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
32% of Patients Achieved Treatment-Free Remission for at Least Six Months in a Single-Arm Trial 93% of Patients Achieved a Platelet Response THOUSAND OAKS, Calif., Oct. 18, 2019 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) today ... Biopharmaceuticals, FDA Amgen, Nplate, romiplostim, Immune Thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 18, 2019 Category: Pharmaceuticals Source Type: news

Nplate (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
THOUSAND OAKS, Calif., Oct. 18, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 18, 2019 Category: Drugs & Pharmacology Source Type: news

Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
The acquisition of Dova provides Sobi with Doptelet (avatrombopag), a differentiated on-market product in Chronic Immune Thrombocytopenia (ITP), a well established and growing market, for Chronic Liver Disease (CLD) and an ongoing phase 3 trial in Chemothe... Biopharmaceuticals, Mergers & Acquisitions Swedish Orphan Biovitrum, Sobi , Dova Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 30, 2019 Category: Pharmaceuticals Source Type: news

MPV, PDW, and PLT Count in ITP and Essential Thrombocytopenia MPV, PDW, and PLT Count in ITP and Essential Thrombocytopenia
This study analyzed and compared MPV and PDW values in immune thrombocytopenic purpura and essential thrombocythemia. How do they compare with values in healthy individuals?Laboratory Medicine (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 27, 2019 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

The Dengue Dance?
Discussion Dengue is an important arboviral infection that affects about 40% of the world population. It is found mainly in topical and subtropical areas of the world mainly in developing countries but it range is spreading including the United States. A review of common arboviruses can be found here. It is a flaviavirus with 4 distinct serotypes named DENV-1 through DENV-4 and is spread by A. aegypti a day biting mosquito. Infection with one serotype confers immunity to that serotype but not the others. It does offer some protection for cross-infection but this only lasts a few months. Incubation period is 3-14 days with ...
Source: PediatricEducation.org - July 29, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Whole-Blood Impedance Aggregometry for Diagnosing HIT Whole-Blood Impedance Aggregometry for Diagnosing HIT
Might whole-blood impedance aggregometry be a faster and simpler alternative to the gold-standard C-serotonin release assay for diagnosis of heparin-induced thrombocytopenia?American Journal of Clinical Pathology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 9, 2019 Category: Allergy & Immunology Tags: Pathology & Lab Medicine Journal Article Source Type: news

FDA Expands Indication for Platelet Booster Avatrombopag FDA Expands Indication for Platelet Booster Avatrombopag
Avatrombopag is now indicated for adults with thrombocytopenia and chronic immune thrombocytopenia; it is already approved for adults with thrombocytopenia and chronic liver disease.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 29, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Dova Pharmaceuticals Announces FDA Approval of Doptelet (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
DURHAM, N.C., June 27, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 27, 2019 Category: Drugs & Pharmacology Source Type: news

Dova receives European marketing authorization
Dova Pharmaceuticals has received the nod from European regulators for the marketing of its drug, providing another avenue of potential for the company as it seeks to successfully land its commercialization effort. The Durham-based company (Nasdaq: DOVA) has received European Commission marketing authorization for Doptelet – its main drug for the treatment of severe thrombocytopenia in adult patients with chronic liver disease. The company's stock was up almost 10 percent Wednesday following… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 25, 2019 Category: American Health Authors: Seth Thomas Gulledge Source Type: news

Dova receives European marketing authorization
Dova Pharmaceuticals has received the nod from European regulators for the marketing of its drug, providing another avenue of potential for the company as it seeks to successfully land its commercialization effort. The Durham-based company (Nasdaq: DOVA) has received European Commission marketing authorization for Doptelet – its main drug for the treatment of severe thrombocytopenia in adult patients with chronic liver disease. The company's stock was up almost 10 percent Wednesday following… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 25, 2019 Category: Biotechnology Authors: Seth Thomas Gulledge Source Type: news

Young Girl Afraid Of IVs Invents ‘ Medi Teddy ’ To Disguise Them
(CNN) — A young girl from Connecticut turned her time spent in the hospital into a chance to help ease the fear of many other young patients. Ella Casano, now 12, was diagnosed with an autoimmune disease called Idiopathic Thrombocytopenia Purpura (ITP) when she was seven. “It’s when her body attacks and destroys its own platelets, so it puts her at higher risk for bleeding or injury, more than most people,” Meg Casano, Ella’s mother, told CNN. Due to ITP, Ella had to have IV infusions every six to eight weeks. As for many young children, and adults, this process scared her. “When I had m...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 14, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Source Type: news

An Assay for Screening of Heparin-Induced Thrombocytopenia An Assay for Screening of Heparin-Induced Thrombocytopenia
This study evaluated the usefulness of an alternative assay, the PIFA PLUSS P4, as a rapid screening test for the diagnosis of heparin-induced thrombocytopenia.Laboratory Medicine (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - May 13, 2019 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

What Clinical Symptoms Can An Infant with Polycythemia Have?
Discussion 1. What are indications for an exchange transfusion? 2. What are potential risks of partial exchange or exchange transfusion? 3. What are causes of anemia in different age groups? Related Cases Disease: Polycythemia | Blood and Blood Disorders Symptom/Presentation: Abnormal Laboratory Test | Respiratory Distress Specialty: Hematology | Neonatology Age: Premature Newborn To Learn More To view pediatric review articles on this topic from the past year check PubMed. Evidence-based medicine information on this topic can be found at SearchingPediatrics.com and the Cochrane Database of Systematic Reviews. Infor...
Source: PediatricEducation.org - April 29, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

ITP and B-cell Lymphoma Feature in Latest BSH Guidance ITP and B-cell Lymphoma Feature in Latest BSH Guidance
Recommendations on tackling osteoporosis in immune thrombocytopenia and mediastinal B-cell lymphoma management are the latest guidance by the British Society for Haematology in a prolific year.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 5, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Flash-Mob Audit Shows Ig Overused in Immune Thrombocytopenia Flash-Mob Audit Shows Ig Overused in Immune Thrombocytopenia
A novel form of audit that pooled data from a large number of centres over a short period of time has revealed that many UK immune thrombocytopenia patients are not receiving recommended therapy.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 2, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Flash Mob Audit Shows Ig Overused in Immune Thrombocytopenia Flash Mob Audit Shows Ig Overused in Immune Thrombocytopenia
A novel form of audit that pooled data from a large number of centres over a short period of time has revealed that many UK immune thrombocytopenia patients are not receiving recommended therapy.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 2, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Ig Overused in Immune Thrombocytopenia, Flash Mob Audit Shows Ig Overused in Immune Thrombocytopenia, Flash Mob Audit Shows
A novel form of audit that pooled data from a large number of centres over a short period of time has revealed that many UK immune thrombocytopenia patients are not receiving recommended therapy.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 2, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes
Cytopenias are an important clinical problem associated with inflammatory disease and infection. We show that specialized phagocytes that internalize red blood cells develop in Toll-like receptor 7 (TLR7)–driven inflammation. TLR7 signaling caused the development of inflammatory hemophagocytes (iHPCs), which resemble splenic red pulp macrophages but are a distinct population derived from Ly6Chi monocytes. iHPCs were responsible for anemia and thrombocytopenia in TLR7-overexpressing mice, which have a macrophage activation syndrome (MAS)–like disease. Interferon regulatory factor 5 (IRF5), associated with MAS, p...
Source: ScienceNOW - January 10, 2019 Category: Science Authors: Akilesh, H. M., Buechler, M. B., Duggan, J. M., Hahn, W. O., Matta, B., Sun, X., Gessay, G., Whalen, E., Mason, M., Presnell, S. R., Elkon, K. B., Lacy-Hulbert, A., Barnes, B. J., Pepper, M., Hamerman, J. A. Tags: Immunology, Online Only r-articles Source Type: news

Amgen Submits Supplemental Biologics License Application For Nplate ® (romiplostim)
Application Seeks to Include Adult Patients who Have had Immune Thrombocytopenia for 12 Months or Less THOUSAND OAKS, Calif., Dec. 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Nplate® (romiplostim) to include the treatment of adult patients with immune thrombocytopenia (ITP) who have had ITP for 12 months or less and an insufficient response to corticosteroids, immunoglobulins or splenectomy. "Patients living with ITP need more flexibility in their treatment options, and we...
Source: Amgen News Release - December 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Choosing Wisely Champions Cut Blood RBC Transfusions, HIT testing Choosing Wisely Champions Cut Blood RBC Transfusions, HIT testing
Two researchers hailed as'Choosing Wisely Champions'describe how they reduced blood transfusions and inappropriate testing for heparin-induced thrombocytopenia (HIT).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Nplate ® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
Application Granted Priority Review Designation Approval Based on Results That Demonstrated Nplate Successfully Increased and Sustained Platelet Counts in Children Affected by Rare Blood Disorder THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have had an insufficient response to corticosteroids, immunoglob...
Source: Amgen News Release - December 14, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

EMA Panel Backs Lusutrombopag for Adults With Liver Disease EMA Panel Backs Lusutrombopag for Adults With Liver Disease
The thrombopoietin receptor agonist is for severe thrombocytopenia in adults with chronic liver disease who are scheduled to undergo an invasive procedure.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

FDA Approves Nplate (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of pediatric... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2018 Category: Drugs & Pharmacology Source Type: news

CNIO finds the origin of a type of thrombocytopenia caused by an oncogene
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) This work has allowed to understand, through the study of MASTL protein, the molecular origin of inherited thrombocytopenia in some patients and to successfully explore therapeutic options on a mouse model.MASTL controls the cytoskeleton, the structure that gives cells their shape and governs their mobility and capacity for grouping.Abnormalities in the cytoskeleton of tumor cells facilitate their spreading throughout the body of cancer patients, which is why studying MASTL might have important implications on how to block metastasis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 31, 2018 Category: Cancer & Oncology Source Type: news

Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
First SYK inhibitor for the treatment of adult chronic ITP SOUTH SAN FRANCISCO, Calif., Oct. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the European Medicines Agency (EMA) has v... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, fostamatinib, TAVALISSE, thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 11, 2018 Category: Pharmaceuticals Source Type: news

Fostamatinib Seems Effective for Immune Thrombocytopenia
Overall response of platelet count ≥ 50,000/ μ L seen in 43 percent of patients (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 5, 2018 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Journal, Source Type: news

Fostamatinib Seems Effective for Immune Thrombocytopenia
WEDNESDAY, Sept. 5, 2018 -- Fostamatinib produces clinically meaningful responses in adults with immune thrombocytopenia (ITP), according a study published in the July issue of the American Journal of Hematology. James Bussel, M.D., from Weill... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 5, 2018 Category: Pharmaceuticals Source Type: news

Sanofi nabs EU approval for first treatment of rare blood-clotting disorder
Cablivi is the first therapeutic approved for the treatment of aTTP, an autoimmune-based blood clotting disorder characterized by extensive clot formation in small blood vessels throughout the body, leading to severe thrombocytopenia (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 4, 2018 Category: Pharmaceuticals Source Type: news

Invasive longhorned tick found for the first time in NYC
The city health department announced Wednesday that the longhorned tick has been spotted in the borough of Staten Island. It is known to transmit severe fever with thrombocytopenia in Asia. (Source: the Mail online | Health)
Source: the Mail online | Health - August 8, 2018 Category: Consumer Health News Source Type: news

FDA Approves Mulpleta (lusutrombopag) for Thrombocytopenia in Adults with Chronic Liver Disease
On July 31, 2018, the Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Approval was based on two... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 1, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Lusutrombopag for Thrombocytopenia in Liver Disease FDA OKs Lusutrombopag for Thrombocytopenia in Liver Disease
The thrombopoietin receptor agonist is for adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 1, 2018 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

FDA approves blood disorder drug made by Japan's Shionogi
The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi& Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease. (Source: Reuters: Health)
Source: Reuters: Health - July 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Spurious Thrombocytopenia in Automated Platelet Count Spurious Thrombocytopenia in Automated Platelet Count
This article underscores the need for healthcare professionals to be aware of the possibility of spurious data from automated PLT counts. What factors might contribute to these false results?Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Pre-op Avatrombopag Curbs Platelet Need in Patients With Liver Disease Pre-op Avatrombopag Curbs Platelet Need in Patients With Liver Disease
Pre-procedural avatrombopag (Doptelet, Dova) may reduce the need for platelet transfusions or rescue procedures for bleeding in patients with chronic liver disease (CLD) and thrombocytopenia, according to findings from two phase 3 trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Approves Doptelet (avatrombopag) for Thrombocytopenia Patients with Chronic Liver Disease who are Undergoing a Medical Procedure
May 21, 2018 -- The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 22, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure
May 21, 2018 -- The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 22, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Platelet Booster for Liver Disease Patients FDA OKs Platelet Booster for Liver Disease Patients
Avatrombopag increases platelet counts and may decrease or eliminate the need for transfusions in patients with liver disease and thrombocytopenia who are to undergo a planned medical or dental procedure.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 21, 2018 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

Toxic thrombocytopenia during Nerium oleander poisoning - Bataille C, Capaldo L, Courtois A, Seguy B, Lotiron C, Labadie M.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - May 21, 2018 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure
FDA approves Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical procedure. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 21, 2018 Category: American Health Source Type: news